Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
Clinical trial NCT07246317 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07246317
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-15
- Primary completion
- 2027-12-31
- Enrollment
- 188
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.